SK14792003A3 - Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok - Google Patents
Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok Download PDFInfo
- Publication number
- SK14792003A3 SK14792003A3 SK1479-2003A SK14792003A SK14792003A3 SK 14792003 A3 SK14792003 A3 SK 14792003A3 SK 14792003 A SK14792003 A SK 14792003A SK 14792003 A3 SK14792003 A3 SK 14792003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- amino acids
- domain
- substances
- use according
- bacterial
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract description 22
- 239000011230 binding agent Substances 0.000 title 1
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 claims abstract description 71
- 210000004027 cell Anatomy 0.000 claims abstract description 37
- 210000004292 cytoskeleton Anatomy 0.000 claims abstract description 31
- 150000001413 amino acids Chemical class 0.000 claims abstract description 29
- 230000001580 bacterial effect Effects 0.000 claims abstract description 28
- 239000000126 substance Substances 0.000 claims abstract description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 15
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 230000036961 partial effect Effects 0.000 claims abstract description 7
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 claims abstract 12
- 241000894006 Bacteria Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 230000000844 anti-bacterial effect Effects 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000000816 peptidomimetic Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 108010077805 Bacterial Proteins Proteins 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 2
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 230000000379 polymerizing effect Effects 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 230000009993 protective function Effects 0.000 claims 2
- 230000002725 anti-mycoplasma Effects 0.000 claims 1
- 238000013519 translation Methods 0.000 abstract description 7
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 59
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 210000000170 cell membrane Anatomy 0.000 description 11
- 210000000805 cytoplasm Anatomy 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002093 peripheral effect Effects 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 5
- 210000003705 ribosome Anatomy 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 150000007650 D alpha amino acids Chemical class 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000252867 Cupriavidus metallidurans Species 0.000 description 1
- -1 D-α-amino acids Chemical class 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 150000007649 L alpha amino acids Chemical class 0.000 description 1
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 1
- 241000203375 Methanococcus voltae Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000193446 Thermoanaerobacterium thermosaccharolyticum Species 0.000 description 1
- 241001468159 Thermoanaerobacterium thermosulfurigenes Species 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10121145 | 2001-04-30 | ||
| DE10129870A DE10129870A1 (de) | 2001-04-30 | 2001-06-21 | Antibakterielles Mittel |
| PCT/EP2002/004410 WO2002087554A2 (de) | 2001-04-30 | 2002-04-22 | Ef-tu-bindende substanzen als ntibakterielles mittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK14792003A3 true SK14792003A3 (sk) | 2004-07-07 |
Family
ID=26009202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1479-2003A SK14792003A3 (sk) | 2001-04-30 | 2002-04-22 | Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1397157A2 (pl) |
| JP (1) | JP2004534016A (pl) |
| CN (1) | CN1298739C (pl) |
| AU (1) | AU2002302555B2 (pl) |
| BG (1) | BG108399A (pl) |
| BR (1) | BR0209282A (pl) |
| CA (1) | CA2445995A1 (pl) |
| CZ (1) | CZ20033271A3 (pl) |
| EE (1) | EE200300530A (pl) |
| HU (1) | HUP0401586A3 (pl) |
| IL (1) | IL158627A0 (pl) |
| MX (1) | MXPA03009954A (pl) |
| NZ (1) | NZ529662A (pl) |
| PL (1) | PL366836A1 (pl) |
| RU (1) | RU2003134636A (pl) |
| SK (1) | SK14792003A3 (pl) |
| WO (1) | WO2002087554A2 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10229645A1 (de) * | 2002-07-02 | 2004-05-19 | Kuchenreuther, Ulrich, Dr. | Zellaufschluss von Bakterien |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| CA2769633C (en) | 2009-07-31 | 2017-06-06 | Thar Pharma, Llc | Crystallization method and bioavailability |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| CN105218668B (zh) * | 2015-10-30 | 2020-03-24 | 山东农业大学 | 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用 |
| WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0466251A1 (en) * | 1990-07-10 | 1992-01-15 | Gist-Brocades N.V. | Elfamycin-resistant mutants |
| AU2717699A (en) * | 1998-01-23 | 1999-08-09 | Akzo Nobel N.V. | Ef-tu mrna as a marker for viability of bacteria |
| US6451556B1 (en) * | 1998-12-21 | 2002-09-17 | Smithkline Beecham Corporation | EF-Tu |
-
2002
- 2002-04-22 SK SK1479-2003A patent/SK14792003A3/sk unknown
- 2002-04-22 AU AU2002302555A patent/AU2002302555B2/en not_active Ceased
- 2002-04-22 CZ CZ20033271A patent/CZ20033271A3/cs unknown
- 2002-04-22 EP EP02730187A patent/EP1397157A2/de not_active Withdrawn
- 2002-04-22 JP JP2002584900A patent/JP2004534016A/ja active Pending
- 2002-04-22 MX MXPA03009954A patent/MXPA03009954A/es unknown
- 2002-04-22 HU HU0401586A patent/HUP0401586A3/hu unknown
- 2002-04-22 PL PL02366836A patent/PL366836A1/pl unknown
- 2002-04-22 WO PCT/EP2002/004410 patent/WO2002087554A2/de not_active Ceased
- 2002-04-22 BR BR0209282-4A patent/BR0209282A/pt not_active Application Discontinuation
- 2002-04-22 CA CA002445995A patent/CA2445995A1/en not_active Abandoned
- 2002-04-22 CN CNB028102185A patent/CN1298739C/zh not_active Expired - Fee Related
- 2002-04-22 EE EEP200300530A patent/EE200300530A/xx unknown
- 2002-04-22 IL IL15862702A patent/IL158627A0/xx unknown
- 2002-04-22 NZ NZ529662A patent/NZ529662A/en unknown
- 2002-04-22 RU RU2003134636/13A patent/RU2003134636A/ru unknown
-
2003
- 2003-12-01 BG BG108399A patent/BG108399A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002087554A3 (de) | 2003-01-30 |
| NZ529662A (en) | 2006-08-31 |
| CA2445995A1 (en) | 2002-11-07 |
| CN1298739C (zh) | 2007-02-07 |
| PL366836A1 (pl) | 2005-02-07 |
| AU2002302555B2 (en) | 2007-08-23 |
| BR0209282A (pt) | 2004-07-27 |
| HUP0401586A3 (en) | 2005-06-28 |
| JP2004534016A (ja) | 2004-11-11 |
| IL158627A0 (en) | 2004-05-12 |
| EE200300530A (et) | 2004-04-15 |
| BG108399A (bg) | 2004-08-31 |
| CZ20033271A3 (en) | 2004-06-16 |
| CN1518455A (zh) | 2004-08-04 |
| EP1397157A2 (de) | 2004-03-17 |
| RU2003134636A (ru) | 2005-04-20 |
| HUP0401586A2 (hu) | 2004-11-29 |
| WO2002087554B1 (de) | 2005-01-27 |
| WO2002087554A2 (de) | 2002-11-07 |
| MXPA03009954A (es) | 2005-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hansen et al. | Intracellular toxicity of proline-rich antimicrobial peptides shuttled into mammalian cells by the cell-penetrating peptide penetratin | |
| Engel et al. | A switch in disulfide linkage during minicollagen assembly in Hydra nematocysts | |
| Nakos et al. | Septin 2/6/7 complexes tune microtubule plus-end growth and EB1 binding in a concentration-and filament-dependent manner | |
| Xie et al. | Novel antimicrobial peptide CPF‐C1 analogs with superior stabilities and activities against multidrug‐resistant bacteria | |
| Rosenfeld et al. | Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides | |
| CN109069693B (zh) | 多肽及其医疗用途 | |
| Chen et al. | Host defense peptide mimicking peptide polymer exerting fast, broad spectrum, and potent activities toward clinically isolated multidrug-resistant bacteria | |
| Nizhnikov et al. | Prions, amyloids, and RNA: Pieces of a puzzle | |
| Lee et al. | A cell adhesive peptide from tropoelastin promotes sequential cell attachment and spreading via distinct receptors | |
| Skerlavaj et al. | Structural and functional analysis of horse cathelicidin peptides | |
| Matharu et al. | Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease | |
| Hansen et al. | The anchorless adhesin Eap (extracellular adherence protein) from Staphylococcus aureus selectively recognizes extracellular matrix aggregates but binds promiscuously to monomeric matrix macromolecules | |
| Li et al. | Effects of N‐terminal modifications on the stability of antimicrobial peptide SAMP‐A4 analogues against protease degradation | |
| SK14792003A3 (sk) | Použitie látok naviazaných na EF-Tu, antibakteriálny prostriedok s obsahom látok naviazaných na EF-Tu a spôsob identifikácie nových antibakteriálnych účinných látok | |
| CA2610791C (en) | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria | |
| Mochizuki et al. | Integrin‐dependent cell behavior on ECM peptide‐conjugated chitosan membranes | |
| US8697651B2 (en) | Amyloid β fibrillogenesis-inhibiting peptide | |
| US20040198643A1 (en) | Antibacterial agent | |
| CN102015757B (zh) | 修饰的Cpn10以及PRR信号 | |
| Oishi et al. | Effects of β-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP (81–145) | |
| US20250101062A1 (en) | Antimicrobial peptides | |
| US7659366B2 (en) | Peptide with putative role in cytoskeletal protection | |
| Park et al. | Synthetic diastereomeric‐antimicrobial peptide: Antibacterial activity against multiple drug resistant clinical isolates | |
| Zobiak | Fibronectin binding protein A-mediated cellular infections by Staphylococcus aureus | |
| Haard | Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo |